Melanoma: An update on systemic therapies

Abstract

Despite advances in early detection as described in part 1 of this continuing medical education series, melanoma continues to be a large contributor to cutaneous cancer-related mortality. In a subset of patients with unresectable or metastatic disease, surgical clearance is often not possible; therefore, systemic and local therapies are considered. The second article in this series provides dermatologists with an up-to-date working knowledge of the treatment options that may be prescribed by oncologists for patients with unresectable stage III, stage IV, and recurrent melanoma.

Keywords: binimetinib; cobimetinib; cutaneous melanoma; dabrafenib; encorafenib; imiquimod; interleukin-2; ipilimumab; laherparepvec; nivolumab; pembrolizumab; talimogene; trametinib; vemurafenib.